Astellas joins forces with Ambrx to develop antibody-drug conjugates

04/8/2013 | Genetic Engineering & Biotechnology News

Astellas Pharma and Ambrx agreed to collaborate in the discovery and development of antibody-drug conjugates for cancer using the latter's site-specific conjugation technology, linkers and drug payloads. Ambrx will get $15 million upfront plus as much as $285 million in milestone fees and sales royalties. The rights to further develop and market the ADCs will go to Astellas.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Director of Operations - GBS
Mayo Clinic
Rochester, MN
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Senior Vice President, Clinical Affairs & Strategic Partnerships
America's Health Insurance Plans (AHIP)
Washington, DC